125 related articles for article (PubMed ID: 38372710)
1. Biologics initiation in moderate versus severe rheumatoid arthritis: real-world experience from a Canadian registry.
Guo N; Li X; Movahedi M; Cesta A; Bombardier C
Clin Exp Rheumatol; 2024 May; 42(5):1067-1074. PubMed ID: 38372710
[TBL] [Abstract][Full Text] [Related]
2. Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry.
Kavanaugh A; Keystone E; Greenberg JD; Reed GW; Griffith JM; Friedman AW; Saunders KC; Ganguli A
Rheumatology (Oxford); 2017 Jul; 56(7):1095-1101. PubMed ID: 28340006
[TBL] [Abstract][Full Text] [Related]
3. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
[TBL] [Abstract][Full Text] [Related]
4. A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization.
Emery P; Solem C; Majer I; Cappelleri JC; Tarallo M
Rheumatol Int; 2015 Nov; 35(11):1837-49. PubMed ID: 26164150
[TBL] [Abstract][Full Text] [Related]
5. Comparison of physical function in early rheumatoid arthritis patients treated with biologics for 1 year who achieved clinical remission or low disease activity.
Hattori Y; Kida D; Kaneko A
Clin Rheumatol; 2017 Nov; 36(11):2607-2612. PubMed ID: 28823077
[TBL] [Abstract][Full Text] [Related]
6. High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.
Iannone F; Gremese E; Gallo G; Sarzi-Puttini P; Botsios C; Trotta F; Gasperini S; Galeazzi M; Adami S; Cantini F; Sebastiani M; Gorla R; Marchesoni A; Giardina A; Foti R; Mele A; Bruschi E; Bagnato G; Erre GL; Lapadula G;
Clin Rheumatol; 2014 Jan; 33(1):31-7. PubMed ID: 23954923
[TBL] [Abstract][Full Text] [Related]
7. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
[TBL] [Abstract][Full Text] [Related]
9. Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status.
Boubouchairopoulou N; Flouri I; Drosos AA; Boki K; Settas L; Zisopoulos D; Skopouli FN; Papadopoulos I; Iliopoulos A; Kyriopoulos J; Boumpas DT; Athanasakis K; Sidiropoulos P
Clin Exp Rheumatol; 2016; 34(6):999-1005. PubMed ID: 27749220
[TBL] [Abstract][Full Text] [Related]
10. Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort.
Kotak S; Mardekian J; Horowicz-Mehler N; Shah A; Burgess A; Kim J; Gemmen E; Boyd H; Koenig A
Value Health; 2015 Sep; 18(6):817-23. PubMed ID: 26409609
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
[TBL] [Abstract][Full Text] [Related]
12. Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow-ups and predictors of achieving treatment target.
Xiang Y; Wang Q; Li H; Duan X; Fang Y; Yang P; Li Q; Wu R; Huo Y; Shi X; Wu Z; Wang Y; Jiang N; Hsieh E; Li M; Tian X; Zeng X;
Int J Rheum Dis; 2020 Dec; 23(12):1719-1727. PubMed ID: 33034424
[TBL] [Abstract][Full Text] [Related]
13. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
14. In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study.
Fanouriakis A; Papalopoulos I; Gergianaki I; Spyrou G; Erden A; Rapsomaniki P; Terizaki M; Avgoustidis N; Repa A; Kougkas N; Bertsias G; Boumpas DT; Sidiropoulos PI
Clin Exp Rheumatol; 2018; 36(5):806-813. PubMed ID: 29533750
[TBL] [Abstract][Full Text] [Related]
15. Long-term remission and biologic persistence rates: 12-year real-world data.
Murray K; Turk M; Alammari Y; Young F; Gallagher P; Saber T; Fearon U; Veale DJ
Arthritis Res Ther; 2021 Jan; 23(1):25. PubMed ID: 33441191
[TBL] [Abstract][Full Text] [Related]
16. Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort.
Holdren M; Schieir O; Bartlett SJ; Bessette L; Boire G; Hazlewood G; Hitchon CA; Keystone E; Tin D; Thorne C; Bykerk VP; Pope JE;
Arthritis Rheumatol; 2021 Jan; 73(1):53-60. PubMed ID: 32852109
[TBL] [Abstract][Full Text] [Related]
17. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
[TBL] [Abstract][Full Text] [Related]
18. Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group.
Genitsaridi I; Flouri I; Plexousakis D; Marias K; Boki K; Skopouli F; Drosos A; Bertsias G; Boumpas D; Sidiropoulos P
Arthritis Res Ther; 2020 Sep; 22(1):226. PubMed ID: 32993800
[TBL] [Abstract][Full Text] [Related]
19. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.
Petro AD; Dougherty J; England BR; Sayles H; Duryee MJ; Hunter CD; Kremer JM; Pappas DA; Robinson WH; Curtis JR; Thiele GM; Mikuls TR
Int Immunopharmacol; 2021 Feb; 91():107260. PubMed ID: 33360371
[TBL] [Abstract][Full Text] [Related]
20. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
